What's on the label is the measured result — net peptide mass, not gross powder weight, plus RP-HPLC purity, on a lot-numbered COA for every batch.
Net peptide mass and RP-HPLC purity — a lot-numbered COA for every batch.
Net peptide mass + HPLC purity, per lot.
PCAC will review 7 peptides for the 503A bulks list, BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, Epitalon. Read our briefing →
PCAC will review 7 peptides for the 503A bulks list. Read →
FDA PCAC reviews 7 peptides in July. Read →
Reference-code fill; Semaglutide identity verified per batch COA · 30 mg
Overview
GLP1-S-30 is a reference code within the metabolic-GLP-1 product family, where the 'S' designator indicates Semaglutide-class material and the '30mg' designates the lyophilized fill quantity per vial. The Semaglutide-class designation places this SKU in the GLP-1 mono-agonist branch of the GLP-1 catalog (distinct from the dual-agonist Tirzepatide-class 'T' codes and the tri-agonist Retatrutide-class 'R' codes). API identity, sequence, and salt form is verified against the released batch-specific COA at order time; for direct end-buyers, the named Semaglutide SKU is the cleaner procurement route because all documentation is attached to an unambiguous molecule rather than a supplier internal code.
Who buys this, and why
Most buyers in this category are 503A and 503B compounding pharmacies fulfilling metabolic and weight-management protocols, plus research labs investigating GLP-1 / GIP / GCG receptor pharmacology. The procurement decision usually hinges on three things: documented purity at scale, a regulatory team that can respond on destination-market questions in writing, and the ability to supply consistent counter-ion form (acetate by default) across recurring orders.
Primary buyer fit: regional distributors and re-sellers.
Specifications
Documentation available on request
Regulatory note
Reference code; verify API identity via batch-specific COA before order placement.
Frequently asked questions
Upstream peptide-manufacturer naming conventions in the metabolic-GLP-1 supply chain use simple letter codes to designate the API class within the product family: 'S' for Semaglutide-class (selective GLP-1 mono-agonist), 'T' for Tirzepatide-class (GIP/GLP-1 dual agonist), 'R' for Retatrutide-class (tri-agonist with glucagon arm). The convention is supplier-internal and not standardized across the industry, individual upstream manufacturers may use different letter mappings. PeptideXpo's customer-facing documentation always confirms the specific API on the released-batch COA regardless of the catalog code; buyers should not rely on the code alone for identity confirmation.
It's possible but uncommon. Upstream reference-code conventions historically used 'S' primarily for Semaglutide because Semaglutide is the higher-volume product in the GLP-1 mono-agonist class. Liraglutide is also a GLP-1 mono-agonist but is older and produced at substantially smaller commercial volumes, so it typically carries a different reference code (sometimes 'L' or a named designation) rather than sharing the 'S' code with Semaglutide. The definitive way to disambiguate is the COA, the mass-spec confirmation will show Semaglutide at ≈4113 Da or Liraglutide at ≈3751 Da, an unambiguous identity check at the batch level. Buyers concerned about the distinction should request explicit clarification at quote stage before order placement.
Subcutaneous Semaglutide formulations (Ozempic, Wegovy) and oral Semaglutide (Rybelsus) contain the same API at the molecular level, the difference is the finished formulation, not the bulk active. Bulk Semaglutide supplied to compounding pharmacies, research labs, and OEM brands is the same molecule regardless of which finished-product type the buyer ultimately produces. The analytical packet confirms identity at the molecular level (HPLC purity, ESI mass spec at 4113 Da, water content, counter-ion), which is sufficient because there is no chemistry-level difference between 'SC-grade' and 'oral-grade' Semaglutide. The differences live in the finished-product formulation (SNAC permeation enhancer for oral, dose-adjusted buffer for SC) rather than in the bulk active itself.
Related peptides
